Andreas Johansson – the new CTO
Andreas Johansson will take over as CTO on January 13, 2020, taking the place of Anders Sjögren who held this position since spring 2017. Anders remains in Lumito's organisation as a senior adviser and will continue to contribute to the company's development. – I look forward to starting as Lumito’s CTO. This is an innovative, […]
Lumito’s main owner, CEO and a member of the board exercise their subscription warrants in full
During the first exercise window, Lumito's major shareholder, Cardeon Futuring Finance (40 percent of which is owned by Masoud Khayyami), Lumito's CEO, Stefan Nilsson, and member of the board Ulf Bladin have exercised all of their Series TO2 warrants to subscribe for shares in Lumito AB. In total, this amounts to 2,130,000 subscription warrants. After the […]
Last day of trading of Lumito TO1 subscription warrants
The last day of trading of Lumito AB (publ) TO1 is Wednesday, 3 July 2019. According to the terms and conditions for series Lumito TO1 subscription warrants, the subscription price shall be reassessed under certain conditions, such as when a preferential rights issue takes place during the warrant life of Lumito TO1. Since Lumito has […]
The last day of trading of paid subscription units (BTU)
The last day of trading of Lumito AB (publ) paid subscription units (BTU) is Tuesday, 2 July 2019. The preferential rights issue that was conducted during May/June 2019 has now been registered with the Swedish Companies Registration Office. The new shares and warrants (after conversion from paid subscription units) are expected to be delivered to […]
Reassessment of subscription price for Lumito TO1 subscription warrants
According to the terms and conditions for series Lumito TO1 subscription warrants, the subscription price shall be reassessed under certain conditions, such as when a preferential rights issue takes place during the warrant life of Lumito TO1. Since Lumito has recently conducted a preferential rights issue, the subscription price for LUMITO TO1 has been reassessed […]
Annual General Meeting of Lumito AB (publ) 2019
The annual general meeting of Lumito AB (publ), held in Lund on 4 June 2019, passed the following resolutions. Resolution on approval of the income statement and balance sheet, etc. The annual general meeting resolved to approve the income statement and balance sheet for the financial year 2018. The Board of Directors and the Managing […]
The Board of Directors’s adjusted proposal for authorization to resolve on new issues
The Board of Directors of Lumito AB (publ) has decided to adjust its proposal under the item 10 on the agenda for the annual general meeting on 4 June 2019. The adjustment means that the following passage is removed: ” Such new issues may in total be comprised of at most the equivalent of 11,200,000 […]
Communiqué from the extraordinary general meeting of Lumito AB (publ)
The extraordinary general meeting of Lumito AB (publ) on 25 April 2019 passed the following resolutions: Item 7 – Decision regarding the approval of the Board of Directors's proposal to issue new shares and warrants (units) Lumito’s Board of Directors has, conditional on the approval of the General Meeting, resolved to conduct a new issue […]
Convocation of Extraordinary General Meeting of shareholders of Lumito AB (publ)
Shareholders of Lumito AB (publ), 556832-0062, are hereby convened to an Extraordinary General Meeting on Thursday, 25 April 2019, at 10:00 a.m. at Magistratsvägen 10, 226 43 Lund, Sweden. A. Right to participate at the Extraordinary General Meeting Shareholders who wish to participate at the extraordinary general meeting must be registered in the share […]
Lumito presents results from the successful proof of concept phase
As previously disclosed the results from the first histological assay (Link to supporting material) (https://www.lumito.se/en/technology/concept-phase/) are very promising and corroborate a rapid development and release of Lumito’s unique products to the market. Lumito performed the assay together with the company’s development partner The Technology Partnership (TTP) and the external research laboratory BioIVT using proof of concept prototypes; tissue staining kit and instrument for […]